Latest Breaking News On - Pierre belichard - Page 1 : vimarsana.com

Enterome s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma

Positive data from the ROSALIE Phase 1/2 trial presented at 2023 SNO Annual MeetingMedian survival of 14.5 months and 18-months survival rate of 4.

France generalBritish columbiaUnited kingdomAshleyr robinsonPierre belichardGuillaume bayreWeid europeDavid reardonHead of external communicationsHealth scienceSociety for neuroProfessor of medicine at harvard medical schoolOncology at dana farber cancer instituteLifesci advisorsAnnual meetingHarvard medical school

EO2401 Plus Nivolumab and Bevacizumab Shows Activity in Progressive/Recurrent Glioblastoma

The use of the first-in-class, microbiome-derived therapeutic vaccine EO2401 in combination with nivolumab with or without bevacizumab produced clinical activity and was well tolerated in patients with progressive/recurrent glioblastoma.

British columbiaUnited kingdomUnited statesDavid reardonPierre belichardEnterome oncomimicsDana farber cancer instituteSociety for neuroAnnual meetingImmuno oncologyBrain cancer

Enterome Selected to The Leukemia & Lymphoma Society s Therapy Acceleration Program

LLS TAP is a strategic funding initiative to accelerate innovative blood cancer therapeutics Strategic equity investment of €3 million to support clinical advancement of EO2463 in Non-Hodgkin's Lymphoma PARIS, Oct.

United statesFrance generalJan fagerbergPierre belichardFast companyLeukemia lymphoma societyHealth scienceInformation resource centerTherapy acceleration programLeukemia lymphoma society therapy acceleration programLymphoma societyHodgkinb cellLore gruenbaumVice presidentAcceleration programChief executive officer

Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease

Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalPierre belichardSylvie berrebi markHealth scienceCancer centerExternal communicationstelMark swallowTumor associated antigensMinimal residual diseaseColorectal cancercolorectal

Enterome s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

Enterome s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

France generalSylvie berrebi markPierre belichardGuillaume bayreJan fagerbergHead of external communicationsHealth scienceInternational conference on malignant lymphomaInternational conferenceMalignant lymphomaChief medical officerHodgkin bcellMark swallowTumor associated antigens